Respira Therapeutics, Inc.
Respira is inhaled pharmaceutical company targeting opportunity in the field of pulmonary arterial hypertension with a risk-reduced development approach.
Respira is an inhaled pharmaceutical company. Respira’s lead product is an inhalable form of an off-patent oral drug for the treatment of pulmonary arterial hypertension (PAH), a deadly medical condition with no current cure. This breakthrough inhaled therapy for PAH delivered by Respira’s AOS-DPI device at a much lower dose than current oral therapies, will result in a more effective direct lung treatment at a much lower nominal dose.